Form 8-K EAGLE PHARMACEUTICALS, For: Dec 27
- Wall St sheds early gains as investors assess Fed minutes
- Cisco (CSCO) Gains as Results, Guidance Signal Supply Constraints are Easing
- Mind Medicine Surges on Connection to Bed Bath & Beyond Whiz Kid Trader Freeman
- This Indicator Signals Apple (AAPL) Stock Could Hit $230 - Bank of America
- Kohl's (KSS) Tumbles on Soft Results and Slashed Guidance
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of||(Commission File Number)||(IRS Employer Identification No.)|
|(Address of principal executive offices)||(Zip Code)|
telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|Item 5.02||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
(b) Departure of Executive Vice President, Chief Medical Officer
On December 27, 2021, Judith Ng-Cashin separated as Executive Vice President, Chief Medical Officer of Eagle Pharmaceuticals, Inc., or the Company. The Company intends to initiate the search for a replacement immediately.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: December 27, 2021||EAGLE PHARMACEUTICALS, INC.|
|By:||/s/ Scott Tarriff|
|Chief Executive Officer|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation
- CFC Issues Second Sustainability Bond to Support Electric Cooperatives
- CarMax Announces Hiring Events for Automotive Technicians and Service Professionals on August 25
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!